Eikon Therapeutics, Inc.
eikontx.comWhat Do They Do?
Develops cancer drug candidates, including immune-stimulating and DNA-repair medicines, for patients with melanoma, lung cancer and other cancers.
10-K, filed Mar 30, 2026
How Are They Changing?
- Net income
-
Sources
10-Q for Q2 FY2026, filed Aug 13, 2026
−$88.4MView ↗
- ▼ −16% (Loss)
- vs −$105.2M in Q2 FY2025
Who Do They Compete With?
Competes with Inimmune, AstraZeneca, Hengrui, Hansoh Pharma, Gilead, Nerviano, Synnovation Therapeutics, Kainos, Duke Street Bio, Acerand Therapeutics, Shenzhen Yangli, Vividion, IDEAYA, Nimbus Therapeutics, and MOMA Therapeutics
10-K, filed Mar 30, 2026We are developing EIK1001, a TLR 7/8 dual-agonist. We are aware of a number of competing product candidates targeting TLR 7/8 in the…View ↗
Loading...
